Satellos (Nasdaq: MSLE, TSX: MSCL), a clinical‑stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, entered into a sales agreement dated August 14, 2026 (the Sales Agreement) with Leerink Partners LLC (Leerink Partners) as sales agent. In accordance with the terms of the Sales Agreement, Satellos may offer and sell its common shares having an aggregate offering price of up to US$50 million (the Offered Shares) through Leerink Partners, as sales agent. This offering is being made exclusively in the United States. No Offered Shares will be offered or sold in Canada or on any trading markets in Canada.
Latham & Watkins LLP represented the sales agent in the offering with a Capital Markets team led by partners Nathan Ajiashvili and Adam Gelardi, with associates KC Sands, Emma Gilmore, and Molly Mitchell. Advice was also provided on IP matters by associates Patrick Chew, Arun Mohan, and Eliot Choy; on healthcare matters by partner Betty Pang; and on FDA matters by partner Nathan Beaton.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.